Progyny, Inc. (PGNY)
| Market Cap | 2.11B +19.9% |
| Revenue (ttm) | 1.31B +5.5% |
| Net Income | 78.63M +48.0% |
| EPS | 0.91 +55.4% |
| Shares Out | 76.73M |
| PE Ratio | 30.27 |
| Forward PE | 12.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,057,192 |
| Open | 27.77 |
| Previous Close | 27.84 |
| Day's Range | 27.43 - 28.41 |
| 52-Week Range | 16.10 - 33.07 |
| Beta | 1.02 |
| Analysts | Strong Buy |
| Price Target | 34.42 (+25.37%) |
| Est. Earnings | Nov 5, 2026 |
About PGNY
Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management s... [Read more]
Financial Performance
In 2025, Progyny's revenue was $1.29 billion, an increase of 10.40% compared to the previous year's $1.17 billion. Earnings were $58.52 million, an increase of 7.70%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for PGNY stock is "Strong Buy." The 12-month stock price target is $34.42, which is an increase of 25.37% from the latest price.
News
Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, announced today that it will present new research evaluating ...
Progyny covered lives outlook ‘clear positive,’ says Leerink
Leerink analyst Michael Cherny views Progyny’s (PGNY) announcement this morning of 1.2M new covered lives from launches throughout the first half of 2027 as a “clear positive.” As Progyny ramps…
Progyny says selling season pacing to ‘record’ level
Progyny (PGNY) earlier revealed insights from the company’s current annual selling season, based on both commitments received to date and anticipated remaining decisions which are expected to contribu...
Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics
Expecting 1.2 Million New Covered Lives from Commitments to Date and Anticipated Remaining Decisions Reflects How Employers are Increasingly Turning to Solutions with a Proven Track Record of Deliver...
Progyny Transcript: Wells Fargo 21st Annual Healthcare Conference
Seasonal utilization softness was noted but is seen as normal, with stable demand expected for the year. Growth is driven by expanding market acceptance, new risk-based products for smaller employers, and ongoing cost containment. Early commitments support confidence in meeting the one million lives target.
Progyny price target raised to $33 from $31 at Citizens
Citizens analyst Constantine Davides raised the firm’s price target on Progyny (PGNY) to $33 from $31 and keeps an Outperform rating on the shares. CalPERS’ selection of Progyny as its…
Progyny, Inc. to Present at the Wells Fargo Healthcare Conference
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Chief Financial Officer Mark Living...
Progyny price target raised to $30 from $27 at JPMorgan
JPMorgan raised the firm’s price target on Progyny (PGNY) to $30 from $27 and keeps a Neutral rating on the shares. The firm updated the company’s model. Published first on…
Progyny initiated with an Overweight at Wells Fargo
Wells Fargo analyst Stan Berenshteyn initiated coverage of Progyny (PGNY) with an Overweight rating and $37 price target The company is “at the intersection” of demographic pressures, corporate wellne...
Progyny price target lowered to $30 from $34 at Barclays
Barclays lowered the firm’s price target on Progyny (PGNY) to $30 from $34 and keeps an Equal Weight rating on the shares. The firm cites larger seasonal headwinds in Q3…
Progyny price target raised to $36 from $33 at Truist
Truist raised the firm’s price target on Progyny (PGNY) to $36 from $33 and keeps a Buy rating on the shares. The firm is updating its estimates after the company’s…
Progyny Transcript: Canaccord Genuity's 46th Annual Growth Conference
Q2 saw pronounced summer seasonality in utilization, but engagement is rebounding and guidance remains strong. Early renewals and new sales commitments have de-risked targets, while product innovation and partnerships, including Progyny Select and Cigna, are expanding market reach and supporting cost control.
Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its CEO Pete Anevski will present at the...
Progyny price target lowered to $35 from $36 at Canaccord
Canaccord lowered the firm’s price target on Progyny (PGNY) to $35 from $36 and keeps a Buy rating on the shares. The firm said 2Q results were solid and noted…
Progyny Earnings Call Transcript: Q2 2026
Record Q2 revenue, gross profit, and adjusted EBITDA were achieved, with strong cash flow and margin expansion. Early sales commitments and high retention de-risk 2027, while guidance projects 5.5–7.5% revenue growth for 2026. Share repurchases reduced shares outstanding by 12.5%.
Progyny Slides: Q2 2026
Progyny has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Progyny Earnings release: Q2 2026
Progyny released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Progyny Quarterly report: Q2 2026
Progyny has published its Q2 2026 quarterly earnings report on August 6, 2026.
Progyny sees Q3 adjusted EPS 50c-52c, consensus 52c
Sees Q3 revenue $335M-$345M, consensus $350.57M. Sees Q3 adjusted EBITDA $56M-$59M.
Progyny raises FY26 adjusted EPS view to $2.04-$2.10 from $1.98-$2.09
Consensus $2.06. Raises FY26 revenue view to $1.36B-$1.39B from $1.37B-$1.41B, consensus $1.38B. Narrows FY26 adjusted EBITDA view to $233M-$240M from $232M-$244M. The company said, “Member engagement...
Progyny reports Q2 EPS 55c, consensus 52c
Reports Q2 revenue $350.51M, consensus $348.65M. “The strong second quarter results reflect that member engagement trended to the higher end of our expectations, as members continued to pursue the ser...
Progyny downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Progyny (PGNY) to Equal Weight from Overweight with a price target of $34, up from $27. The firm’s analysis of fertility clinic web traffic shows some modest deceleration…
Progyny price target raised to $40 from $30 at BTIG
BTIG raised the firm’s price target on Progyny (PGNY) to $40 from $30 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period en...
Progyny price target raised to $38 from $30 at Leerink
Leerink analyst Michael Cherny raised the firm’s price target on Progyny (PGNY) to $38 from $30 and keeps an Outperform rating on the shares.